The extended-release formulation of Klacid OD is utilized in clinical settings involving acute or unstable symptom patterns, where symptomatic support is required to manage bacterial infections. Its application is appropriate for clinical scenarios characterized by acute or disruptive symptoms.

Klacid OD is commonly used for conditions presenting with systemic or localized discomfort, particularly in situations involving symptoms related to inflammatory or irritative states. These include community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis, and acute maxillary sinusitis. It is also utilized as a component in multi-drug regimens for conditions marked by increased physiological stress, where it is applied to address symptoms linked to Helicobacter pylori and peptic ulcer discomfort.

Quick Fact: Supportive Management for Respiratory Discomfort

Klacid OD is commonly used during phases when symptoms become more noticeable, such as acute exacerbations of bronchitis, and is relevant in the management of symptoms related to physical discomfort like cough and chest congestion.

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Rules for Klacid OD

Klacid OD (Clarithromycin Extended-Release) is generally permitted for use in adults and adolescents 12 years of age and older. The extended-release formulation is not recommended for children younger than 12 years.

Contraindicated Populations (Must Not Use)	Condition-Specific Limitations (Caution)
Hypersensitivity to Clarithromycin or any macrolide antibiotic.	Impaired Hepatic Function (caution advised).
History of QT prolongation or ventricular cardiac arrhythmia (e.g., Torsades de Pointes).	Moderate to severe renal impairment (CrCl 30 mL/min) [Source 1.5].
Uncorrected hypokalemia or hypomagnesemia.	Coronary artery disease or severe cardiac insufficiency.
Severe hepatic failure in combination with renal impairment.	Myasthenia Gravis (may worsen symptoms).
Severe renal impairment (Creatinine Clearance < 30 mL/min) [Source 1.5].

Regulatory documents state that use is not recommended during pregnancy or lactation (breastfeeding). The absolute contraindication for severe renal impairment is specific to the extended-release tablet because the regulatory required dose reduction cannot be achieved with this formulation. These rules define eligibility boundaries based on patient risk factors and physiological status.

Interactions with other medicines and products

Klacid OD (Clarithromycin) interactions are primarily classified as pharmacokinetic and are largely driven by its effect as a strong inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme, which is critical for the metabolism of numerous co-administered drugs. This inhibition leads to increased plasma concentrations (exposure) of those medicines.

Formal Contraindicated Combinations

The co-administration of Klacid OD is strictly prohibited with certain medicinal products due to the risk of serious or fatal adverse events:

Classification	Examples of Prohibited Drugs
Cardiovascular Risk	Astemizole, Cisapride, Pimozide, Terfenadine, Ivabradine, Ranolazine
Ergot Toxicity Risk	Ergot Alkaloids (Ergotamine, Dihydroergotamine)
Myopathy/Rhabdomyolysis Risk	Lovastatin, Simvastatin

Clinically Significant Interactions

Clarithromycin also affects the P-glycoprotein (P-gp) efflux pump, leading to increased exposure of drugs like Digoxin. With Oral Anticoagulants (e.g., Warfarin), a pharmacodynamic interaction increases the risk of serious hemorrhage, necessitating frequent monitoring of the International Normalized Ratio (INR). The extended-release formulation must be taken with food to maintain optimal exposure, as administration without food results in approximately 30% lower absorption. Furthermore, an increase in the severity of Colchicine toxicity is documented, particularly in the elderly and those with renal impairment.

Targeted Inhibition of Bacterial Protein Synthesis

The action of Klacid OD (Clarithromycin) is strictly defined by its role as a specific inhibitor that targets the bacterial machinery for protein synthesis. The drug binds reversibly to the 23S ribosomal RNA (rRNA) component within the pathogen's 50S ribosomal subunit. This interaction physically blocks the crucial processes of translocation and peptidyl transferase activity, thereby preventing the elongation of the peptide chain. This molecular blockade modifies the bacterial growth pathway, resulting in a bacteriostatic effect at the cellular level.

Metabolite Action and Intracellular Targeting

The primary metabolite, 14-hydroxyclarithromycin, is microbiologically active and co-contributes to the antimicrobial effect; the metabolite exhibits greater intrinsic activity against certain bacteria like Haemophilus influenzae. Furthermore, the drug's high lipophilicity facilitates its accumulation in high concentrations within phagocytes (immune cells). This mechanism utilizes host cells to transport the drug to the site of inflammation and facilitates action against intracellular pathogens.

Functional Constraints

The inhibitory mechanism is constrained by bacterial resistance involving enzymatic methylation or point mutations in the 23S rRNA binding site. This target modification reduces the drug's affinity for the 50S subunit, preventing it from reaching the necessary inhibitory concentration.

Klacid OD (Clarithromycin Extended-Release) is an oral medication indicated for use in adults and adolescents 12 years of age and older. Its administration follows a once daily frequency, typically involving a total dose of 1000 mg (two 500 mg tablets). This extended-release format is designed to deliver the active ingredient over a sustained period of 24 hours.

To ensure the controlled release mechanism functions correctly, the tablets must be swallowed whole and must not be crushed, broken, or chewed. The dose is administered with food to facilitate optimal absorption of clarithromycin. Treatment courses generally range between 7 to 14 days, depending on the specific application.

This formulation is not recommended for use in children younger than 12 years, who are typically administered the immediate-release suspension. Furthermore, the extended-release tablet is contraindicated in adults with severe renal impairment (creatinine clearance less than 30 mL/min), as the non-divisible 500 mg tablets prevent the necessary dose reduction. In instances where a dose is missed, standard practice involves taking it as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to avoid doubling the dose.

The research evidence for Klacid OD (Clarithromycin Extended-Release) is derived from official clinical studies that investigate how the medicine performs in group settings. This overview describes the structure of that research, the outcomes the studies were designed to measure, and what remains uncertain, without providing individual clinical advice or treatment recommendations.

---

Clinical Research Structure by Indication

Studies in Acute Respiratory Conditions

The primary evidence base was established in well-structured Randomized Controlled Trials (RCTs) and meta-analyses exploring acute respiratory infections. For Community-Acquired Pneumonia (CAP), studies examined composite outcomes related to the evolution of symptoms and monitored severe outcomes like the need for mechanical ventilation. For Acute Exacerbations of Chronic Bronchitis (AECB), trials evaluated measurements related to symptoms such as breathing difficulty and tracked the frequency of subsequent exacerbations over study periods.

Other Research Contexts

Klacid OD was also evaluated in short-term RCTs for Acute Maxillary Sinusitis, where outcomes like pain and congestion were monitored, noting the structural difficulty in confirming bacterial cause before treatment. Furthermore, the drug was studied as a component within multi-drug combination therapies for H. pylori eradication, where primary outcomes included microbiological eradication and observed ulcer resolution. The specific role of the extended-release formulation within these combinations is often structurally difficult to isolate.

---

Long-Term Data and Research Gaps

The core studies evaluating Klacid OD primarily focused on short-term changes and immediate outcomes, with follow-up typically limited to 10 to 30 days. Data for sustained measurements of outcomes or recurrence monitoring beyond this period are limited. While research on older adults has been conducted, results apply only to the specific patient groups studied, and evidence remains insufficient for patients with severe kidney impairment. The overall regulatory research base also documents structural limitations, including the challenge of increasing clarithromycin resistance across global populations.

Key Studies & References

1. Clarithromycin Extended-Release Tablet: General Drug Information

Common questions about Klacid OD (FAQ)

Q: Can I drink alcohol while I am taking Klacid OD?

Official drug labels for clarithromycin do not contain a specific warning or contraindication against the consumption of alcohol while taking Klacid OD. However, when recovering from any infection that requires an antibiotic, general medical consideration suggests avoiding alcohol. Concerns regarding this topic should be discussed with a healthcare provider.

Q: Does Klacid OD interact with any common foods or supplements?

The extended-release tablet of Klacid OD is recommended to be taken with food to help achieve optimal absorption of the active ingredient. Administration without food has been shown to result in lower absorption of the medication. While official regulatory information focuses primarily on drug-drug interactions, it does not typically include a comprehensive list of common supplements or foods to avoid.

Q: Is Klacid OD safe for use during pregnancy or while breastfeeding?

According to official regulatory information, use during pregnancy is not recommended unless there is no appropriate alternative and the potential benefit is believed to outweigh the potential risk. Clarithromycin has been found to be excreted into breast milk. Any decision regarding use during pregnancy or breastfeeding should be made in consultation with a healthcare provider.

Q: How much time does it take for Klacid OD to start working to clear up my infection?

Klacid OD is an extended-release medicine, meaning it is engineered to release the active ingredient continuously over a 24-hour period. While the drug starts to absorb quickly, clinical studies typically measure the effectiveness of the treatment by monitoring the resolution of infection symptoms over the full 7 to 14 day treatment course. The full effect of the medicine is related to the completion of the prescribed treatment course.

Q: What are the signs of an allergic reaction to Klacid OD?

The medicine is prohibited in patients with a known history of hypersensitivity or allergy to clarithromycin or other macrolide antibiotics. Regulatory documents warn that serious allergic reactions are possible, which may include symptoms like severe skin conditions (such as Stevens-Johnson Syndrome), or swelling of the face, lips, or throat. Any concern about a suspected allergic reaction requires immediate medical assessment.

How to Store and Dispose of Klacid OD (Clarithromycin Extended-Release Tablets)

Klacid OD must be stored under specific conditions to maintain the stability of the active ingredient, clarithromycin.

Storage Requirements

• Temperature: Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
• Protection: The medicine must be protected from light and moisture.
• Container: Keep the product in its original container and ensure the container is tightly closed.
• Safety: The tablets must be stored out of the sight and reach of children.

Disposal

Discard any unused or expired Klacid OD safely. If a drug take-back program is unavailable, mix the whole tablets with an undesirable substance (such as dirt or kitty litter), place the mixture in a sealed bag, and throw it into the household trash. Do not crush the tablets. Do not dispose of this medicine by flushing it down a toilet or pouring it down a drain.